Study of Haemodialysis Patients Switching From Aranesp to Biosimilar
NCT02191150 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 272
Last updated 2016-02-08
Summary
The study will obtain data to show insight into clinical outcomes of patients switching from Darbepoetin Alfa to a epoetin alfa biosimilar.
Conditions
- Anaemia
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
MD · Amgen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-06-30
- Primary Completion
- 2015-04-30
- Completion
- 2015-05-31
Countries
- Australia
- Bulgaria
- Germany
- Greece
- Italy
- Poland
- Spain
Study Locations
More Related Trials
-
Clinical Validation Study for Optimization of Anemia MAnagement in Hemodialysis Patients With End Stage Kidney Disease Using the Dialysis Anemia TReatmenT Model
NCT05936021 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
NCT02753894 ·Status: COMPLETED ·Phase: PHASE2
-
Study of South African Dialysis Patients
NCT01890577 ·Status: TERMINATED
-
A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD
NCT03831607 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
NCT01742611 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
NCT00892749 ·Status: COMPLETED ·Phase: PHASE3
-
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
NCT03428594 ·Status: COMPLETED ·Phase: PHASE3
-
Renal Impairment Study
NCT00863161 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis
NCT00035178 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
NCT01737879 ·Status: TERMINATED ·Phase: PHASE4
-
A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
NCT00863707 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
NCT04527328 ·Status: COMPLETED ·Phase: NA
-
PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease
NCT01581073 ·Status: COMPLETED ·Phase: PHASE3
-
An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients
NCT01590823 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease
NCT03976115 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis
NCT01241539 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
NCT07323095 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
NCT07315360 ·Status: RECRUITING ·Phase: PHASE1
-
A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
NCT01057407 ·Status: COMPLETED ·Phase: PHASE3
-
Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients
NCT03844555 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
NCT01346215 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
NCT01017276 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis
NCT01503021 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis
NCT03612856 ·Status: COMPLETED ·Phase: PHASE2
-
16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
NCT02260193 ·Status: COMPLETED ·Phase: PHASE2